TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00604344
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782273
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Study: NCT03386344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT06247267
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
Study: NCT01870297
Drug: LY3025876
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT01870297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT02634528
Drug: Julphar Insulin N (human isophane insulin)
Normalized name: insulin isophane Pen Injector [Novolin N]
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational insulin: Julphar N (human isophane insulin), biosimilar
Study: NCT02634528
Drug: Huminsulin® Basal (NPH, human isophane insulin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
Study: NCT00490243
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02722278
Drug: Oral Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
Study: NCT02722278
Drug: Axiron Testosterone Topical Solution
Normalized name: testosterone Topical Solution [Axiron]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
Study: NCT00346359
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01290471
Drug: U3-1565
Approvals — FDA: no, EMA: no, PMDA: no
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
Study: NCT01182285
Drug: Liothyronine Sodium
Normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
Study: NCT00841321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule orally twice a day for 12 weeks
Study: NCT02276937
Drug: DVC1-0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
Study: NCT02607293
Drug: Gonal-f®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
Study: NCT02607293
Drug: Long GnRH agonist
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
Study: NCT03419806
Drug: Infudopa i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Study: NCT03419806
Drug: Infudopa s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Study: NCT03419806
Drug: LCIG (Duodopa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg.
Study: NCT04061772
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide injection
Study: NCT03856294
Drug: Rikkunshito
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
Study: NCT01504178
Drug: injection of placebo of L-Dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: performed at D28
Study: NCT00041210
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00041210
Drug: Stanford V regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00041210
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00578929
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 1 or 2 sprays per nostril twice daily
Study: NCT01670032
Drug: Experimental: CD07223 1.5 % Topical Gel BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study: NCT01670032
Drug: Experimental: CD07223 1.5% Topical Gel TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study: NCT01670032
Drug: Placebo Comparator: CD07223 vehicle gel BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study: NCT01670032
Drug: Placebo Comparator: CD07223 vehicle gel TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Study: NCT01106586
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF 200/300 mg tablet administered orally once daily
Study: NCT01106586
Drug: ATV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ATV administered orally once daily
Study: NCT01106586
Drug: RTV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match RTV administered orally once daily
Study: NCT01106586
Drug: FTC/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match FTC/TDF administered orally once daily
Study: NCT00424476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Study: NCT01645241
Drug: gonadotropins plus GnRH antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00694902
Drug: GSK610677
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
Study: NCT00694902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study: NCT00422162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule by mouth
Study: NCT05540951
Drug: VIC
Normalized name: Vicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
Study: NCT01429168
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 60-mg tablet orally daily
Study: NCT01429168
Drug: Placebo for etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 60-mg tablet orally daily
Study: NCT03529942
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 32 mg FX006 IA injection
Study: NCT00538499
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00720629
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Study: NCT00720629
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Study: NCT01474265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 tablets per day, oral use
Study: NCT01474265
Drug: Nicorette TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mg per day, transdermal use (patches)
Study: NCT04156685
Drug: Part A, Reference (D635 10/500mg, Astrazeneca)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day. Under fasting condition
Study: NCT04156685
Drug: Part B, Reference (D635 10/500mg, Astrazeneca)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day. Under fed condition
Study: NCT00748098
Drug: GSK1838262 Extended Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1838262 extended release tablets
Study: NCT00748098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01116830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally daily for 6 weeks
Study: NCT01116830
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily orally for 6 weeks
Study: NCT01116830
Drug: Standard Antipsychotic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Study: NCT00665392
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m² day 1 to day 5. 3 cycles
Study: NCT00238745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02632045
Drug: LEE-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg capsule (3x 200 mg capsules)
Study: NCT02632045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg capsule (3x 200 mg capsules)
Study: NCT04021277
Drug: 20 uL/kg PS101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Study: NCT04021277
Drug: 40 uL/kg PS101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Study: NCT02268526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV q 4weeks
Study: NCT02451553
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01075815
Drug: Recombinant follicle-stimulating hormone (rFSH)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00231166
Drug: HCD122
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699178
Drug: Oral testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
Study: NCT00872404
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg/3 weeks
Study: NCT02114502
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL oral rinse four times a day from Day -9 until discharge.
Study: NCT02114502
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Study: NCT01196741
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
Study: NCT03246919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered after delivery of the placenta
Study: NCT02367248
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Study: NCT04382053
Drug: Standard of Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study: NCT03829566
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A medication used as chemotherapy and to suppress the immune system
Study: NCT01844063
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
Study: NCT02195180
Drug: ERY001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02195180
Drug: 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
Study: NCT03689452
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free normal saline will be used as described in arm/group description section.
Study: NCT00857909
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet twice a day
Study: NCT00857909
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet twice a day
Study: NCT00857909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00857909
Drug: Placebo and spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg twice daily
Study: NCT00857909
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg twice daily
Study: NCT02319304
Drug: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm description
Study: NCT01379989
Drug: Pegylated Lipoxomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m² i.v.
Study: NCT02057367
Drug: Scalp block with 0.5% plain Marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
Study: NCT02556918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill daily starting one day prior to surgery until discharge from the hospital.
Study: NCT02556918
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study: NCT02057367
Drug: Scalp block with 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior scalp block will be done by using 0.9% normal saline 20 ml.
Study: NCT00747149
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT01191450
Drug: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg
Normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
Study: NCT01191450
Drug: Higroton® Laboratório Novartis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
Study: NCT01513447
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
Study: NCT01905371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01537120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01346826
Drug: Standard 2 hours-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.
Study: NCT01276509
Drug: PF-00547659 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo delivered SC, 3 doses separated by 4 weeks
Study: NCT01276509
Drug: PF-00547659 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Study: NCT01276509
Drug: PF-00547659 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Study: NCT01276509
Drug: PF-00547659 SC injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
Study: NCT02228083
Drug: Lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
Study: NCT01034683
Drug: lobaplatin , 5-FU ,leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.